DS-8500a

DRUG5 trials

Sponsors

Daiichi Sankyo Co., Ltd., Daiichi Sankyo

Conditions

Drug Pharmacokinetics in Healthy VolunteersPharmacokineticsType 2 Diabetes MellitusType2 Diabetes Mellitus

Phase 1

A Study to Determine the Effects of Itraconazole on the Pharmacokinetics (PK) of DS-8500 in Healthy Subjects

CompletedNCT02790671

Daiichi SankyoPharmacokinetics

Start: 2016-05-31End: 2016-06-30Updated: 2019-02-12

A Study Assessing the Mass Balance of a Single Oral Dose of [14C] DS-8500a in Healthy Subjects

CompletedNCT02790684

Daiichi SankyoPharmacokinetics

Start: 2016-05-31End: 2016-06-30Updated: 2019-02-12

Effect of Repeated Doses of DS-8500a on Pharmacokinetics of Rosuvastatin in Healthy Volunteers

CompletedNCT03699774

Daiichi SankyoDrug Pharmacokinetics in Healthy Volunteers

Start: 2015-05-12End: 2015-07-06Updated: 2019-02-12

Unknown Phase

A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)

CompletedNCT02628392

Daiichi Sankyo Co., Ltd.Type2 Diabetes Mellitus

Start: 2015-11-30End: 2016-09-30Updated: 2019-02-12

An Exploratory Study of DS-8500a on Beta Cell Function Using Hyperglycemic Clamp

CompletedNCT02669732

Daiichi Sankyo Co., Ltd.Type 2 Diabetes Mellitus

Start: 2016-01-31End: 2016-10-31Updated: 2019-02-12

Related Papers

Effect of DS-8500a, a Novel G Protein-Coupled Receptor 119 Agonist, on the Pharmacokinetics of Rosuvastatin and Atorvastatin in Healthy Subjects.

2019-10-014 citations

G protein-coupled receptor 119 agonist DS-8500a effects on pancreatic β-cells in Japanese type 2 diabetes mellitus patients.

2018-05-0413 citations

Efficacy and Safety of GPR119 Agonist DS-8500a in Japanese Patients with Type 2 Diabetes: a Randomized, Double-Blind, Placebo-Controlled, 12-Week Study.

2018-02-2727 citations